In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug delivery

The development of clinically acceptable albumin-based nanoparticle formulations for use in pulmonary drug delivery has been hindered by concerns about the toxicity of nanomaterials in the lungs combined with a lack of information on albumin nanoparticle clearance kinetics and biodistribution. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Woods, A., Patel, A., Spina, D., Riffo-Vasquez, Y., Babin-Morgan, A., de Rosales, R.T.M., Sunassee, K., Clark, S., Collins, H., Bruce, K., Dailey, L.A., Forbes, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Publishers 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674532/
https://www.ncbi.nlm.nih.gov/pubmed/25980621
http://dx.doi.org/10.1016/j.jconrel.2015.05.269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674532/
https://www.ncbi.nlm.nih.gov/pubmed/25980621
http://dx.doi.org/10.1016/j.jconrel.2015.05.269

Ejemplares similares